SERCHEM - Investment into decontamination and hygiene chemical producer

SERCHEM

Investment into decontamination and
hygiene chemical producer

Investment into decontamination and hygiene chemical producer

Alinea has advised on the investment into Serchem Limited (“Serchem”). Serchem is a designer and producer of decontamination and hygiene chemicals for the healthcare and facilities management industries in the UK and internationally.  

The investor team will work alongside the current shareholders to help guide and support Serchem through its next phase of growth and further enhance its offering to customers.

The current shareholders, Alison Arnold, Commercial Director and Andrew Arnold, Technical Director remain involved on a daily basis and committed to the long-term growth of the company.

“In recent years Serchem has continued to attract an increasing level of business both in the UK and internationally, driven by its commitment to premium products and service.

We want to not only successfully deliver on that growth but further strengthen our customer relationships and position in the market.

As part of achieving that we have carefully selected a group of experienced investors to actively support the team, I look forward to working alongside them in this next phase of growth”.
Alison Arnold, Commercial Director & Shareholder

As part of the investor team Alinea have joined forces with longstanding client and operating partner Richard Hale after his successful and longstanding ownership of Deritend Industries.

Commenting on the investment, Oliver Wadlow said “I have known Serchem and the shareholders for several years. Serchem’s commitment to quality products and service has given it an outstanding reputation, we are excited to see the investor team and current shareholders work together, enabling them to build on the strong platform they have developed”.

Legal advice was provided to the investor team by Higgs LLP, Mark Gibson from DWF and Martin Poole from Azets provided legal and financial advice respectively to the current shareholders.